Activity
Cassava Sciences Agrees to $40 Million Settlement with SEC Over Manipulated Alzheimer’s Trial Data
Cassava Sciences, SEC charges, Alzheimer’s drug, simufilam, manipulated trial data, settlement, misleading statements
Cassava Sciences Agrees to $40 Million Settlement with SEC Over Misleading Alzheimer’s Drug Trial Claims
Cassava Sciences, SEC settlement, Alzheimer’s drug trial, misleading claims, data manipulation, simufilam, pharmaceutical fraud
Emergent BioSolutions Secures $400 Million in Orders for Smallpox and Mpox Vaccines Amid Ongoing Outbreak
Emergent BioSolutions, smallpox, mpox, vaccine orders, biodefense, global health preparedness
Pfizer Withdraws Sickle Cell Disease Treatment Oxbryta Globally Due to Safety Concerns
Pfizer, Oxbryta, sickle cell disease, global market withdrawal, safety concerns, clinical trials, vaso-occlusive crises, fatal events
Telix Acquires RLS to Bolster Radiopharmaceutical Manufacturing and Distribution in North America
Telix Pharmaceuticals, RLS (USA) Inc., radiopharmaceutical manufacturing, distribution, acquisition, North America, radiometal production network
Eli Lilly and Novo Nordisk Support OAC’s Your Weight Matters Campaign Amidst Competitive Weight Loss Drug Market
Eli Lilly, Novo Nordisk, OAC, Your Weight Matters, weight loss drugs, GLP-1, obesity care, pharmaceutical industry
Organon Expands Dermatology Portfolio with $1.2B Acquisition of Dermavant and VTAMA Cream
Organon, Dermavant, VTAMA cream, dermatology, acquisition, steroid-free skin cream, plaque psoriasis, atopic dermatitis
Organon Expands Dermatology Portfolio with Acquisition of Dermavant for Up to $1.2 Billion
Organon, Dermavant, Roivant, dermatology, VTAMA cream, tapinarof, plaque psoriasis, atopic dermatitis, acquisition
Biopharma Leaders Navigate AI ‘Hype Cycle’: Bayer, Daiichi Sankyo, and argenx Share Insights on AI Implementation in Marketing
AI in biopharma marketing, Bayer, Daiichi Sankyo, argenx, AI implementation, biopharma industry, AI hype cycle
AstraZeneca’s Imfinzi Demonstrates Significant Survival Benefit in Muscle-Invasive Bladder Cancer, Raises Questions on FDA Approval for Perioperative Design
AstraZeneca, Imfinzi, durvalumab, muscle-invasive bladder cancer, MIBC, perioperative trial design, FDA approval, survival benefit